Korea Bizwire, Author at Be Korea-savvy | Page 3 of 2844
South Korean Art Market Booming

South Korean Art Market Booming

SEOUL, Dec. 6 (Korea Bizwire) — With South Korea’s art market reaching new highs, the total volume of successful bids has set a new record this year. The Korea Arts Management Service reported that 296.8 billion won (US$250 million) had been spent on artwork auctions this year as of November. The size of the art [...]

Extension of Vaccine Pass to Teens Met with Angry Reaction by Students, Parents

Extension of Vaccine Pass to Teens Met with Angry Reaction by Students, Parents

SEOUL, Dec. 6 (Korea Bizwire) — Teenage students and parents are mounting protests over the looming enforcement of vaccine passports for adolescents, saying the measure amounts to forcing vaccination upon minors and could hinder the learning rights of the unvaccinated. Amid the COVID-19 resurgence and a pileup of infections among young students, the government announced [...]

S. Korean Retail Investors Buy Chinese EV ETF, Sell Samsung and SK hynix Shares

S. Korean Retail Investors Buy Chinese EV ETF, Sell Samsung and SK hynix Shares

SEOUL, Dec. 6 (Korea Bizwire) — South Korean retail investors have been snapping up shares of electric vehicle-themed exchange traded fund (ETF) while dumping shares of Samsung Electronics Co. and SK hynix Inc., data showed Sunday. The most-sold stocks by retail investors during the five weeks from Nov. 1 to Dec. 3 were the two [...]

Hyundai Motor Group Tops China’s CSR List for 6th Straight Year

Hyundai Motor Group Tops China’s CSR List for 6th Straight Year

SEOUL, Dec. 6 (Korea Bizwire) — Hyundai Motor Group ranked first on a list measuring carmakers’ corporate social responsibility (CSR) activities in China for the sixth consecutive year. The South Korea’s top automotive conglomerate, which has Hyundai Motor Co. and Kia Corp. under its wing, announced that in the 2021 China CSR development index evaluated [...]

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals Under the Age of 12

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals Under the Age of 12

SHANGHAI, China, Dec. 6 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”) has expanded the emergency use authorization (“EUA”) for etesevimab (JS016/LY-CoV016) and bamlanivimab (LY-CoV555) administered together [...]